Blog

NEWARK, CA / ACCESS Newswire / January 7, 2026 / Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference taking place January 12-15, 2026 in San Francisco, CA. The Company will also participate in one-on-one meetings.

44th Annual J.P. Morgan Healthcare Conference – January 12-15, 2026

Format: Company Presentation

Day/Time: Tuesday, January 13 at 8:15 AM PST

Webcast: https://jpmorgan.metameetings.net/events/healthcare26/sessions/317262-protagonist-therapeutics-inc/webcast?gpu_only=true&kiosk=true

If you are interested in meeting with the Protagonist team during the conference, please reach out to your J.P. Morgan representative.

A replay of the presentation will be available on the Company’s Investor Relations Events and Presentations webpage for one year following the event.

About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist’s proprietary discovery platform are currently in advanced Phase 3 clinical development, with a New Drug Application (NDA) for icotrokinra submitted to the FDA in July, and an NDA for rusfertide submitted in December 2025. Icotrokinra (formerly, JNJ-2113), is a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor (“IL-23R”), which is licensed to Janssen Biotech, Inc., a Johnson & Johnson company. Following icotrokinra’s joint discovery by Protagonist and Johnson & Johnson scientists pursuant to the companies’ IL-23R collaboration, Protagonist was primarily responsible for the development of icotrokinra through Phase 1, with Johnson & Johnson assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of preclinical stage drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, and the oral hepcidin program.

More information on Protagonist, its pipeline drug candidates, and clinical studies can be found on the Company’s website at https://www.protagonist-inc.com.

Investor Relations Contact

Corey Davis, Ph.D.
LifeSci Advisors
cdavis@lifesciadvisors.com

Media Contact

Virginia Amann
ENTENTE Network of Companies
virginiaamann@ententeinc.com

SOURCE: Protagonist Therapeutics

View the original press release on ACCESS Newswire

This news release constitutes a “designated news release” for the purposes of the Company’s amended and restated prospectus supplement dated November 18, 2025, to its Canadian short form base shelf prospectus dated May 15, 2025.

MIAMI, FL / ACCESS Newswire / January 7, 2026 / Digi Power X Inc. (“Digi Power X” or the “Company“) (Nasdaq:DGXX)(TSXV:DGX), an innovative energy infrastructure company, today announced that it has entered into a non-binding letter of intent (the “LOI”) with Omnis Pleasants LLC (“Pleasants”), owner of the Pleasants Power Station, a 1.3 gigawatt (“GW”) power generation facility located in West Virginia, to pursue a strategic partnership supporting large-scale artificial intelligence (“AI”) and high-performance computing infrastructure.

Pursuant to the terms of the LOI, the parties intend to conduct a comprehensive load and interconnection study of up to 1.3 GW, evaluating long-term power availability and grid connectivity for energy-intensive computing applications.

The proposed strategic partnership also contemplates a long-term lease of up to 200 acres of land, that would enable Digi Power X to deploy AI and advanced computing infrastructure utilizing its proprietary ARMS modular Tier III data center platform.

In addition, the LOI establishes a framework for potential equity alignment, including a mutual equity exchange between Digi Power X and Pleasants based on fair market valuation, as well as a defined pathway for Digi Power X to acquire an equity ownership stake in excess of 10% in the power plant entity, subject to definitive documentation, agreed valuation, financing structure and applicable regulatory approvals.

Separately, Digi Power X and Pleasants intend to collaborate on a hydrogen-transition feasibility study for Digi Power X’s New York power assets, aligning with broader decarbonization and energy-transition initiatives.

“This strategic partnership will advance our strategy of pairing large-scale, grid-connected power assets with next-generation AI infrastructure,” said Michel Amar, CEO of Digi Power X. “Pleasants offers the scale, land availability and electrical infrastructure required to support AI and high-performance computing at meaningful, long-term levels.”

The parties expect to initiate the load study within 30 days and target execution of definitive agreements within approximately 90 days, subject to customary conditions and approvals.

About Digi Power X

Digi Power X is an innovative energy infrastructure company that develops Tier III-certified modular AI data centers and drives the expansion of sustainable energy assets.

For further information, please contact:

Michel Amar, Chief Executive Officer
Digi Power X Inc.
www.digipowerx.com

Investor Relations
T: 888-474-9222
Email: IR@digihostpower.com

Cautionary Statement

Trading in the securities of the Company should be considered highly speculative. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements

Except for the statements of historical fact, this news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) that are based on expectations, estimates and projections as at the date of this news release and are covered by safe harbors under Canadian and United States securities laws. Forward-looking information in this news release includes information about the Company’s expectations concerning the strategic partnership with Pleasants, as well as the potential further improvements to profitability and efficiency across the Company’s operations, including, as a result of the Company’s expansion efforts, potential for the Company’s long-term growth and clean energy strategy, and the business goals and objectives of the Company. Factors that could cause actual results to differ materially from those described in such forward-looking information include, but are not limited to: the Company’s ability to enter into definitive documentation in respect of the proposed strategic partnership with Omnis and to achieve the anticipated benefits of such strategic partnership; delivery of equipment and implementation of systems may not occur on the timelines anticipated by the Company or at all; the results of a proposed comprehensive load and interconnection study; future capital needs and uncertainty of additional financing; share dilution resulting from equity issuances; risks relating to the strategy of maintaining and increasing Bitcoin holdings and the impact of depreciating Bitcoin prices on working capital; effects on Bitcoin prices as a result of the most recent Bitcoin halving; development of additional facilities and installation of infrastructure to expand operations may not be completed on the timelines anticipated by the Company, or at all; ability to access additional power from the local power grid and realize the potential of the clean energy strategy on terms which are economic or at all; a decrease in cryptocurrency pricing, volume of transaction activity or generally, the profitability of cryptocurrency mining; further improvements to profitability and efficiency may not be realized; development of additional facilities to expand operations may not be completed on the timelines anticipated by the Company; ability to access additional power from the local power grid; an increase in natural gas prices may negatively affect the profitability of the Company’s power plant; the digital currency market; the Company’s ability to successfully mine digital currency on the cloud; the Company may not be able to profitably liquidate its current digital currency inventory, or at all; a decline in digital currency prices may have a significant negative impact on the Company’s operations; the volatility of digital currency prices; and other related risks as more fully set out in the Annual Information Form of the Company and other documents disclosed under the Company’s filings at www.sedarplus.ca and www.SEC.gov/EDGAR. The forward-looking information in this news release reflects the current expectations, assumptions and/or beliefs of the Company based on information currently available to the Company. In connection with the forward-looking information contained in this news release, the Company has made assumptions about, among other things, the current profitability in mining cryptocurrency (including pricing and volume of current transaction activity); profitable use of the Company’s assets going forward; the Company’s ability to profitably liquidate its digital currency inventory as required; historical prices of digital currencies and the ability of the Company to mine digital currencies on the cloud will be consistent with historical prices; the ability to maintain reliable and economical sources of power to run its cryptocurrency mining assets; the negative impact of regulatory changes in the energy regimes in the jurisdictions in which the Company operates; and there will be no regulation or law that will prevent the Company from operating its business. The Company has also assumed that no significant events occur outside of the Company’s normal course of business. Although the Company believes that the assumptions inherent in the forward-looking information are reasonable, forward-looking information is not a guarantee of future performance and accordingly undue reliance should not be put on such information due to the inherent uncertainties therein. The Company undertakes no obligation to revise or update any forward-looking information other than as required by applicable law.

SOURCE: Digi Power X Inc.

View the original press release on ACCESS Newswire

• Integration of prescription drug dispensing optimization aritifical intelligence platform EinsteinRx™ into pharmacy client point-of-sales systems has commenced

• EinsteinRx integration streamlining effort focuses on reducing onboarding process friction and speeding time to implementation prior to scaling pharmacy marketing effort

• Company expects to onboard up to 500 pharmacies per month into formal Wellgistics Pharmacy Network by year end 2026

• Manufacturer supplier relationship expansion effort focused on diabetes, weight loss, cardiometabolic & Long COVID patients that existing pharmacy clients already serve

• PharmacyChain™ blockchain-enabled healthcare smart contract development resource assessment ongoing

TAMPA, FLORIDA / ACCESS Newswire / January 7, 2026 / Wellgistics Health, Inc. (“Wellgistics”) (NASDAQ:WGRX), a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence (‘AI’) platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™, today provided a corporate outlook for 2026 to stakeholders.

“Three months following my return to the role of President at Wellgistics, the Company now has a clear direction as we begin a hyper-focused operational execution phase,” said Prashant Patel, RPh, President & Interim-CEO of Wellgistics Health. “In 2026 we will focus squarely on the implementation of our EinsteinRx™ AI platform into pharmacy client point of sale systems, onboarding and increasing the percentage of our existing 6,500+ independent pharmacy customers that convert into our official Wellgistics pharmacy network (the ‘Wellgistics Pharmacy Network’). The key benefit for pharmacies enrolling in the Wellgistics Pharmacy Network will be the integration of patient-specific health information pulled from authorized provider databases with ‘just-in-time’ prescription optimization tools to empower our network’s pharmacists to educate both providers and patients on the best personalized prescription drug selection and prescription drug-adjacent products & services that are associated with the best patient outcomes. We have already started the Wellgistics Pharmacy Network integration process with our closest pharmacy customers and are currently optimizing the onboarding process to make it as seamless as possible for pharmacists, leveraging client feedback to improve speed of deployment and reduce process friction. Once sufficiently optimized, we intend to accelerate the pharmacy conversion marketing effort as we also look to expand our prescription drug manufacturer supplier relationships. We have set a goal of reaching a Wellgistics Pharmacy Network onboarding rate of up to 500 pharmacies per month by year end 2026.”

Mr. Patel continued, “While SGLT-2 drug Brenzavvy® for the diabetes market is the first product that we are focused on optimizing EinsteinRx for, we intend to quickly expand our branded manufacturer relationships to include other products that primarily target similar patient populations that make up a significant proportion of the patients Wellgistics Pharmacy Network pharmacies serve, including patients who have been prescribed GLP-1 agonist drugs and other drugs associated with cardiometabolic disease, such as Long COVID.”

The US diabetes market was estimated to be $48 billion in 2024, growing to $79 billions by 2031 according to iData Research. The North American GLP-1 agonist market was estimated to be $53 billion in 2025, respected to grow to $156 billion by 2030 according to Grandview Research. The US cardiometabolic disorders market was estimated to be $46 billion in 2024, expected to grow to $85 billion by 2031 according to Mobility Forsights. Over 18 million patients in the United States lose an annual average of over $9,000 per patient, resulting in total lost wages estimated at over $170 billion annually according to research published in Nature Publication Journals Primary Care Respiratory Medicine.

“Concurrent with this onboarding optimization effort, our technology team has been working to complete its assessment of the resources required to establish PharmacyChain,” added Mr. Patel. “We will very soon provide updates on this exciting effort that we expect will dramatically improve efficiency in the healthcare delivery market. PharmacyChain is being developed to implement end-to-end smart contracts to drastically reduce the administrative burden associated with optimal healthcare delivery, improve payer transparency and significantly increase the rate of timely insurance reimbursements for pharmacies, providers and other stakeholders in the United States while simultaneously rooting out fraud, waste and abuse in the healthcare system.”

About Wellgistics Health, Inc.

Wellgistics Health (NASDAQ: WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispending journey. Its integrated platform connects 6,500+ pharmacies (the “Wellgistics Pharmacy Network”) and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.

For more information, visit www.wellgisticshealth.com.

Forward-Looking Statements

This press release contains forward‑looking statements within the meaning of the federal securities laws, including, without limitation, statements regarding the parties’ plans to negotiate definitive agreements, potential implementation, adoption, performance, revenue sharing, and other anticipated benefits of the contemplated collaboration. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including those described in DataVault AI, Inc.’s and Wellgistics Health, Inc.’s filings with the SEC. Forward‑looking statements speak only as of the date hereof, and neither company undertakes any obligation to update them except as required by law. Additional factors are discussed in Wellgistics Health’s filings with the SEC, available at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction, and there shall be no sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Wellgistics Media & Investor Contact

Media:
media@wellgisticshealth.com

Investor Relations:
IR@wellgisticshealth.com

SOURCE: Wellgistics Health, Inc.

View the original press release on ACCESS Newswire

FDA feedback supports 505(b)(2) filing in H2 2026; No additional studies required beyond current planned 32-subject clinical trial

ESTERO, FL / ACCESS Newswire / January 7, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) (“Aspire” or the “Company”), a biopharmaceutical company developing multi-faceted patent-pending drug delivery technology, today announced the successful outcome of a Type B pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA). The meeting provided a clear regulatory roadmap for the Company’s investigational new drug, acetylsalicylic acid 162 mg sublingual powder (OTASA), designed for the emergency treatment of suspected acute myocardial infarction (heart attack).

The FDA’s written responses provide the necessary guidance to finalize the Company’s clinical and regulatory development strategy. Based on FDA’s feedback, Aspire anticipates completing a currently planned multicenter crossover clinical trial and then submitting a Section 505(b)(2) New Drug Application. The clinical trial will evaluate serum thromboxane B₂ (TxB₂) inhibition in 32 healthy volunteers, comparing OTASA (162 mg) against the current standard of care-two chewed 81 mg aspirin tablets.

“The FDA’s constructive feedback validates our development path and brings us one step closer to providing a faster-acting intervention for heart attack patients,” said Kraig Higginson, Interim CEO of Aspire. “Aligning with the Agency on our clinical requirements significantly de-risks our timeline and we believe the FDA’s response leaves the door open for Aspire to obtain breakthrough therapy status for our OTASA product. We believe OTASA has the potential to become the market-leading emergency treatment, and this regulatory clarity is a vital milestone as we engage in active discussions with potential commercial partners.”

Clinical Data Highlights
The pre-IND submission was supported by data from a pilot, proof-of-concept clinical trial demonstrating:

• Rapid Absorption: OTASA produced higher and faster mean plasma concentrations of acetylsalicylic acid (ASA) compared to chewed aspirin tablets.

• Rapid Platelet Inhibition: The sublingual formulation inhibited serum TxB₂-a key biomarker for platelet aggregation-within the first two minutes of administration.

• Safety Profile: In initial evaluations, the product was safe and well-tolerated, with no reported adverse events.

About Aspire Biopharma Holdings, Inc.

Aspire Biopharma has developed a patent-pending sublingual delivery technology that can deliver drugs to the body rapidly and precisely. This technology offers the potential to improve effectiveness and reduce side effects by going directly to the bloodstream and avoiding the gastrointestinal tract. Aspire Biopharma’s delivery technology can be applied to many different active pharmaceutical ingredients (APIs) and other bioactive substances, spanning both small and large molecule therapeutics, nutraceuticals and supplements.

For more information, please visit www.aspirebiolabs.com

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the “safe harbor” provisions created by those laws. Aspire’s forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would,” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and

developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug candidates, if approved; Aspire’s acetylsalicylic acid sublingual powder, 162 mg (OTASA) is an investigational new drug and has not been approved for marketing for any indication, our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our drug candidates; that the Company will be able to meet the deadlines or conditions imposed by the Hearings Panel or regain compliance with all applicable requirements for continued listing, and other risks and uncertainties set forth in “Risk Factors” in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

Aspire Biopharma Holdings, Inc.

Contact:

PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com

SOURCE: Aspire Biopharma Holdings, Inc.

View the original press release on ACCESS Newswire

Tax professionals say multiple income streams often lead to under-withholding, leaving workers surprised by tax balances they didn’t anticipate.

IRVINE, CA / ACCESS Newswire / January 7, 2026 / As more Americans take on second jobs or combine traditional employment with freelance or gig work, tax professionals are warning that paycheck withholding errors are becoming a growing source of unexpected IRS bills. Clear Start Tax, a national tax resolution firm, says many workers assume taxes are being handled correctly – only to discover a balance due when they file.

According to Clear Start Tax, the issue often arises when employees split income across multiple employers. Each employer withholds taxes as if that job is the worker’s only source of income, which can result in too little tax being withheld overall, especially for federal income taxes.

“Each paycheck may look fine on its own, but combined, the withholding often falls short,” said a Clear Start Tax spokesperson. “That gap doesn’t show up until tax time, when people are hit with a bill they weren’t expecting.”

The problem can be compounded when one of the jobs is freelance or contract-based. Unlike traditional employment, 1099 income typically has no taxes withheld at all, requiring workers to make estimated payments throughout the year. Many don’t realize this obligation until penalties and interest are already in play.

Clear Start Tax notes that workers earning additional income may also be pushed into a higher tax bracket, increasing the amount owed even if total earnings don’t feel dramatically higher.

“We see a lot of confusion from people who say, ‘I didn’t make that much more,’” the spokesperson added. “But tax brackets, credits, and withholding calculations can change quickly when you add a second income source.”

Tax professionals say the issue is especially common among teachers, healthcare workers, hospitality staff, and others who pick up seasonal or part-time work. Without proactive adjustments to withholding or estimated payments, even modest second incomes can create tax shortfalls.

With IRS enforcement and collection activity increasing, Clear Start Tax encourages workers with multiple jobs to review their withholding before filing season arrives.

“A small adjustment during the year can prevent a much bigger problem later,” the spokesperson said. “The goal is to avoid surprises – not deal with them after the IRS gets involved.”

By answering a few simple questions, taxpayers can find out if they’re eligible for the IRS Fresh Start Program and take the first step toward resolving their tax debt.

About Clear Start Tax
Clear Start Tax is a national tax resolution firm that helps individuals and businesses address IRS and state tax issues, including back taxes, penalties, and collection actions. The firm focuses on educating taxpayers about compliance requirements and guiding them through available relief options to achieve lasting financial stability.

Need Help With Back Taxes?
Click the link below:
https://clearstarttax.com/qualifytoday/
(888) 710-3533

Contact Information
Clear Start Tax
Corporate Communications Department
tech@clearstarttax.com
(949) 800-4011

SOURCE: Clear Start Tax

View the original press release on ACCESS Newswire

Company Successfully Executed Distribution of $500,000 in Cash and $500,000 in BONK Digital Assets Prior to Year-End; Validates “Revenue-to-Treasury” Business Model

SCOTTSDALE, ARIZONA / ACCESS Newswire / January 7, 2026 / Bonk, Inc. (Nasdaq:BNKK) today announced a material strengthening of its balance sheet for the fiscal quarter ended December 31, 2025. During the fourth quarter, the Company successfully executed a transfer of $1 million in value generated from its majority revenue interest in BONK.fun.

This transfer, completed prior to the fiscal year-end, represents the first major realized distribution following the Company’s acquisition of a majority interest in the platform. The $1 million injection was composed of:

• $500,000 in Cash: Providing non-dilutive liquidity to support corporate operations.

• $500,000 in BONK Digital Assets: Directly increasing the Company’s treasury holdings in alignment with its strategic accumulation target.

Proof of Execution This transaction represents the tangible financial result of the explosive growth reported by BONK.fun in December. By capturing this revenue and moving it directly onto the public company’s books before the close of Q4, Bonk, Inc. has demonstrated the speed and efficiency of its new business model.

Strategic Impact The successful execution of this $1 million injection creates a dual-benefit for shareholders in the Q4 financial results:

1. Balance Sheet Expansion: Increased current assets without issuing a single new share of stock.

2. Treasury Growth: Executed on the Company’s stated goal to secure 5% of the circulating supply, using operational profit rather than investor capital to fund the purchase.

Leadership Commentary “This is our strategy in action,” said Jarrett Boon, CEO of Bonk, Inc. “We told our shareholders that acquiring a majority interest in BONK.fun would transform our financials. We proved it in Q4. We didn’t just report gross transaction volume; we moved real value-cash and assets-onto our balance sheet before the year closed. This $1 million injection validates our timing, our structure, and our ability to monetize the digital asset economy for our public shareholders.”

Mitchell Rudy (a.k.a. Nom), Board Director, added, “We are building a machine that turns ecosystem activity into treasury value. This transfer demonstrates exactly how that machine works: BONK.fun generated high-margin yield, and we deployed a significant portion of that yield back into the underlying asset. Adding $500,000 in BONK assets to our vault in a single transaction was a major step toward our accumulation goals, and doing it alongside a $500,000 cash injection proves the financial robustness of the platform.”

About Bonk, Inc. Bonk, Inc. (Nasdaq:BNKK) is a company evolving to bridge the gap between traditional public markets and the digital asset ecosystem. Through its subsidiary BONK Holdings LLC, the Company executes a strategy focused on acquiring revenue-generating assets within the decentralized finance space. The Company also operates a growing beverage division holding the patented Sure Shot and Yerbaé brands.

Investor Relations Contact: Phone: 888.257.8061 Email: investors@bonkdat.com

Forward-Looking Statements: This press release contains forward-looking statements regarding the Company’s financial position, revenue generation, and treasury accumulation goals. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results could differ materially due to factors such as market volatility in the digital asset sector, performance of the BONK.fun platform, and other risks detailed in Bonk, Inc.’s filings with the Securities and Exchange Commission. The Company assumes no obligation to update forward-looking statements.

SOURCE: Bonk, Inc.

View the original press release on ACCESS Newswire